Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Self-Administered Icatibant for Acute HAE Attacks
NCT01457430Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Dec 2011
- Primary completion
- Apr 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of icatibant in hereditary angioedema (HAE), sponsored by Massachusetts General Hospital. Primary endpoint: Time to Complete or Near Complete Resolution From Onset of Symptoms. Started Dec 2011; status: completed.
02
Drugs
icatibant
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT01457430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01457430.